

Long-Acting Injectable PrEP: Early Implementers breakout

February 29, 2024

Ending the Epidemic





No faculty/presenters, planners, including CME committee members, have relavent financial relationships with commercial interests.

CHCN is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians.

CHCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Plan and purpose for this session



Learning objectives:

- 1. Examine a sample clinical workflow/protocol for long acting injectable PrEP
- 1. Understand the staffing models for offering long acting injectable PrEP
- 1. Understand the basics of insurance coverage/drug assistance program



Introductions



- 1. Name, pronouns, role, organization
- 2. Your injectable program: approximate # of patients on injectable PrEP (if any)
- 3. What are you hoping to get out of this session?



LAI PrEP Guest Presenters

- Asian Health Services Alex Iling
- LifeLong Medical Care
 - East Oakland Health Center David Greenberg, RN
 - **TRUST Health Center Maria Zimmerman, RN**



Incredible Injectables!



The Need for LAI PrEP:

- Key populations have been left behind by daily oral PrEP
- With perfect use, oral PrEP and injectable PrEP are equally efficacious
- With typical use, injectable PrEP offers superior protection against HIV

Goals for today:

- Explore the role that LAI PrEP can play in filling critical gaps in PrEP access for patients
- Consider your clinic's ability to offer LAI PrEP (even in a limited scope)
- Leave with the tools and connections you need to take the next step toward expanding LAI PrEP access at your clinic



Incredible Injectables!

Accomplishments in 2023:

- Quarterly East Bay HIV provider conferences to discuss injectable ART and PrEP.
- Injectables resource page: ebgtz.org/resource/injectables

2023: ~163 people at FQHCs on long-acting injectable meds!



LAI PrEP Sample Workflows

Asian Health Services - Alex Iling



LAI PrEP - LifeLong Protocol

Lifelong Long-Acting Injectable PrEP Protocol

Adapted from Ward 86 Long-Acting Injectable ARV Protocol

Background

APRETUDE is an injectable prescription medicine to prevent HIV infection in adults. APRETUDE contains only one medication, <u>cabotegravir</u>, an integrase strand transfer inhibitor (INSTI). APRETUDE is administered as intramuscular (IM) gluteal injection only and must be administered by a licensed health care professional. Per FDA labeling, APRETUDE may be started with an oral lead in to assess tolerability or it may be started direct-to-inject.

Recommended Dosing

APRETUDE is approved for every 8-week dosing. The recommended loading and maintenance dosing is as follows:

Optional Oral Lead In x 28 days

Cabotegravir 30mg once daily with a meal

Every 8 Week Intramuscular Injection Dosing Schedule in Adults



* Maintenance doses may be given up to 7 days early or late Other administration considerations: Use a 2-inch needle for BMI≥30 kg/m²

Process for Referral and Initiation

Provider:

- Use .SA185APRETUDEINITIATION smartphrase to ensure you are reviewing and ordering all needed items.
- Consider providing a 30-day supply of alternative oral PrEP regimen (can be prior regimen)
- Notify identified PrEP navigator of plan to start APRETUDE and if using oral lead in order from Theracom with delivery to office or patient home as preferred.
- Order loading and maintenance doses for delivery to clinic from AHF pharmacy or Walgreens community pharmacy.
- Notify MAC and RNs of medication order and plan to ensure medications are refrigerated immediately upon delivery.
- Order APRETUDE to Pharmacy

1E				Order Search			- D X
APRETU	DE	P				Browse Erefe	rence List Eaclify List Database
III Pan	els	(No results found)				Search panels by us	er ,P
🛱 Me	dicatio	ons A					I (Ait+Shift+2)
		Name	Code	Porrrulary	Copary	Coverage	Drug Type
ŝ		APRETUDE 600 MG/3 ML (200 MG/ML) IM SUSPENSION, EXTENDED REL.	. 164051				Drand Rx
- 12		CAROTEGRAVIR ER 600 MG/4 ML (200 MG/ML) IM SUSPENSION/EXTENDS.	164050				Genetic Rx

Order APRETUDE on MAR

Panels (No results found)	Ø			growse Preference List Esciity L	ist Qatabase
Panels (No results found)					
				Search panels by user	
Medications (No results found)					
Clinic-Administered Medications 8					
Name		Dose	Route Frequ., Disp., Disp., Ref Formulary	Code Type End., Section PrefLis	t Copay Cove
# APRETUDE 600 MG/S ML (200 MG/ML)	IN SUSPENSION, EXTENDED RELEASE [164051]	eco reg	intra	164051 Medica Facility SA185.	

PrEP Navigator:

- Ensure we have 2 alternate contacts for patient on file (with signed authorization to release form)
- Follow-up with pharmacies to ensure delivery of medication and will facilitate RN appointment for injection.
- Maintains an EPIC Shared Patient List of patients who are on APRETUDE, ensures that future
 appointments and labs are scheduled appropriately, and conducts reminder calls to patients for
 all APRETUDE related visits

LAI PrEP - LifeLong EPIC smart phrases

LifeLong Apretude Epic Checklist

Apretude Initiation Checklist:

1) Confirm eligibility (based on CDC criteria below or clinical judgment)

[] anal or vaginal sex in the past 6 months AND [] sexual partner with HIV (especially if the partner has an unknown or detectable viral

load) OR

[] have not consistently used a condom OR

[] have been diagnosed with a sexually transmitted disease in the past 6 months

OR if injecting drugs

share injection equipment

[] have injection partner with HIV

2) Evaluate HIV Status

[] NONE of the following symptoms today or in the past 30 days:

- fever with sore throat
- rash
- swollen lymph nodes

Headache

*if any of the above symptoms, order HIV RNA Viral Load + 4th gen HIV Ag/Ab to rule out acute HIV before offering PrEP.

[] Have you used any PrEP/PEP pills in the past 3 months or injections in the past 12 months?

If YES:

[] order HIV RNA Viral Load + 4th gen HIV Ag/Ab; consider awaiting results before prescribing PrEP if patient reports gaps in PrEP or inconsistent use

If NO:

[] HIV RNA Viral Load negative result must be documented within 1 week prior to initiation of CAB-LA OR

[] perform a Rapid HIV Ag/Ab fingerstick to document negative status AND obtain blood draw for HIV RNA Viral Load on the same-day to confirm status (ok to administer CAB-LA while lab test is pending).


*Oral fluid HIV tests should be avoided, as they are less sensitive for the detection of acute/recent HIV infection.

3) [] Medications reviewed for drug interactions (see resources below)

4) Counseling


[] Injection site reactions (pain, tenderness, induration) were most frequent after the first 2-3 injections. These were generally mild to moderate, lasting only a few days, and improved with supportive management.

Patient Lists



My Lists		EO Apretude Patie	ents I Paleit				
🕨 🦻 ED Cabenuva Patients 👘	4	Patient	*	Last Viral Load	Last Office Visit and Provider	Next Appt Data	PCP
▶ 🕏 EO MPX Vaccine List	- 1			<20 NOT DETECTED	BOHMAN, COREY		BOHMAN, COREY
+ 💎 HIV Over 50 List - Project Corn-	- 1			SECTION DE LECTED	Bolling Conci		Donier H, Conc.
🕨 📴 Tobacco List (test)							
🕨 🐲 Tobacco Treatment							
> Shared Patient Lists							
C EO ACCESS Patient List							
EO Apretude Patients 1	1						
HIV Clinic - TRUST 58	5						

Fills out .SA185APRETUDEHX under specialty notes





LAI PrEP Standard Work Template

Standard Work Instructions

Title: Injectable PrEP Workflow					
Performed By: Navigator, Nurses, Providers		Date: 9/28/23			
Owner: Albert Liu	Revised By:	Revision #:			

Purpose:

Major Steps		Details (relevant details and tips, diagram, workflow, picture, time grid)	Time	Reason
	Screening			
1.	Obtain insurance information	 Navigator obtains participant's insurance card and information 	5 min	
2.	Discuss PrEP options	 Navigator discusses PrEP options and elicits interest in long-acting injectable PrEP 	15 min	
3.	Viiv Connect Form	 Navigator fills out Apretude Enrollment form with Patient Information (Section 1), Insurance Information, (Section 2), Prescriber information (Section 3), Medication information (Sections 4-5, 7-8) <u>English Form</u> <u>Spanish Form</u> 	10 min	
4.	Complete Viiv Connect Form	 Have participant complete Sections 1 (including signature), PAP (Section 6) 	5 min	
5.	Explain insurance process	 Explain insurance approval process. Explain that staff will contact participant to schedule their first injection once insurance approvals are received. 	5 min	
6.	Discussion with Provider	 Provider provides general information about Apretude, including injection location and schedule, and review side effects, including injection site reactions. Discuss preference for direct-to-inject vs. oral lead in 	10 min	
7.	Medical history and physical exam	 Provider completes baseline medical history, reviews medications, and physical exam (including inspection of bilateral gluteal regions) 	20 min	



LAI PrEP FAQs



Trainings Our Programs Resources About Us Contact

Injectable PrEP Frequently Asked Questions - Clinical

The information in this FAQ provides general guidance and reflects what is currently understood about Cabotegravir-LA (Apretude) based on data from HPTN 083 and post-marketing experience. Readers should consult the package insert and/or obtain expert guidance in the management of individual patients.

1. What is the time to protection of CAB-LA for injectable PrEP?	0
2. What is important to know about side effects of CAB-LA?	0
3. Is an oral PrEP lead-in recommended before a patient receives the first CAB-LA injection?	0
4. Can oral cabotegravir be used for oral PrEP prior to the first injection of CAB-LA?	0
5. Under what circumstances is oral cabotegravir approved for PrEP?	0
6. What if a patient wants to take the cabotegravir oral lead in for only one week, and then switch to the injectable form?	0

https://californiaptc.com/prep-learning-collaboratives/longacting-injectable-prep/injectable-prep-frequently-askedquestions/

Q&A with community providers

- 1. How did your clinic decide they would start offering LAI PrEP?
- 2. How did you get your clinic leadership on board?
- 3. What is your staffing set up?
- 4. How do you make injection visits billable?
- 5. Who does each of the major steps at your clinic?
 - Patient education
 - Determining eligibility
 - Ordering, tracking, storing medication
 - Delivering injection & tracking labs/next dose
- 6. What were your early challenges in implementation and what strategies have you used to address them?
- 7. What are your ongoing biggest challenges in real-world implementation?
- 8. Open Q&A around starting up services

Injectables resources

Check out the <u>EBGTZ Injectables webpage</u> for the latest local resources: <u>ebgtz.org/resource/injectables</u>

Clinical guides, protocols and EHR tools

•EBGTZ Injectable PrEP Quick Guide

•Pacific AETC Injectables Toolkit, including clinical protocols, checklists and patient education

•SFDPH Injectable PrEP Pocket Card PDF; also on this webpage

•Ward 86 Long-acting Injectable Antiretroviral Protocol

LifeLong Long-acting Injectable ARV Protocol

•Epic SmartPhrases for Cabenuva and Apretude from LifeLong

• Injectable PrEP Clinical FAQs (Eng/Spa)- CA Prevention Training Center

•Injectable PrEP Access and Financing FAQs (Eng/Spa) - Ca Prevention Training Center

Training videos

•Apretude clinical training video from Viiv: click to watch here or watch on the Viiv website

•Ventrogluteal injection site training video

•Thigh injection (vastus lateralis) site training video



Ending the HIV Epidemic

Next steps and upcoming meetings

Upcoming events and working group meetings:

- Next clinical conference discussing injectables: May 14, 2024, 12-1 pm on Zoom.
- More East Bay HIV meetings here: <u>www.EBGTZ.org/events</u>
- Join our East Bay HIV network lists/groups: email ZJ Eskman: zj@ebgtz.org

Thank you & Evaluation!

